Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fernando C Fervenza

Showing results (1-10 of 349) with videos related to

Pageof 35
Sort By:
Nephron. Clinical Practice|December 17, 2010
Rituximab in ANCA-associated vasculitis: fad or fact?Fernando C Fervenza
International Journal of Dermatology|March 26, 2003
Henoch-Schönlein purpura nephritisFernando C Fervenza
Clinical Journal of the American Society of Nephrology : CJASN|May 28, 2009
Overcoming calcineurin dependence in membranous nephropathy: is rituximab the answer?Fernando C Fervenza
Clinical Journal of the American Society of Nephrology : CJASN|July 27, 2013
A patient with nephrotic-range proteinuria and focal global glomerulosclerosisFernando C Fervenza
Nature Reviews. Nephrology|November 21, 2012
Vasculitis: Refining phenotypes in ANCA-associated vasculitisFernando C Fervenza, Ulrich Specks
Nature Reviews. Nephrology|July 21, 2025
Antigens in membranous nephropathy: discovery and clinical implicationsSanjeev Sethi, Fernando C Fervenza
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 13, 2013
Frequent-relapsing, steroid-dependent minimal change disease: is rituximab the answer?Fernando C Fervenza, Sanjeev Sethi
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 6, 2019
Editorial: a new era in anti-neutrophil cytoplasmic antibody vasculitisDenis Fouque, Fernando C Fervenza
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 20, 2023
Membranous nephropathy-diagnosis and identification of target antigensSanjeev Sethi, Fernando C Fervenza
Clinical Kidney Journal|September 5, 2023
Anti-CD20 should be the first-line treatment in high-risk membranous nephropathyLadan Zand, Fernando C Fervenza
Pageof 35

Showing results (1-10 of 349) with videos related to

Sort By:
Pageof 35
Nephron. Clinical Practice|December 17, 2010
Rituximab in ANCA-associated vasculitis: fad or fact?Fernando C Fervenza
International Journal of Dermatology|March 26, 2003
Henoch-Schönlein purpura nephritisFernando C Fervenza
Clinical Journal of the American Society of Nephrology : CJASN|May 28, 2009
Overcoming calcineurin dependence in membranous nephropathy: is rituximab the answer?Fernando C Fervenza
Clinical Journal of the American Society of Nephrology : CJASN|July 27, 2013
A patient with nephrotic-range proteinuria and focal global glomerulosclerosisFernando C Fervenza
Nature Reviews. Nephrology|November 21, 2012
Vasculitis: Refining phenotypes in ANCA-associated vasculitisFernando C Fervenza, Ulrich Specks
Nature Reviews. Nephrology|July 21, 2025
Antigens in membranous nephropathy: discovery and clinical implicationsSanjeev Sethi, Fernando C Fervenza
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 13, 2013
Frequent-relapsing, steroid-dependent minimal change disease: is rituximab the answer?Fernando C Fervenza, Sanjeev Sethi
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 6, 2019
Editorial: a new era in anti-neutrophil cytoplasmic antibody vasculitisDenis Fouque, Fernando C Fervenza
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 20, 2023
Membranous nephropathy-diagnosis and identification of target antigensSanjeev Sethi, Fernando C Fervenza
Clinical Kidney Journal|September 5, 2023
Anti-CD20 should be the first-line treatment in high-risk membranous nephropathyLadan Zand, Fernando C Fervenza
Pageof 35